Scientists have discovered that a protein linked to prostate cancer is associated with more aggressive disease – it could be a new target for treatment and used to help predict who will become resistant to hormone therapy.

The ICR strongly welcomes the news that a new targeted drug, capivasertib, has been approved by the US FDA for treating the most common type of advanced breast cancer. The drug was discovered by pharmaceutical company AstraZeneca following a programme of drug discovery research at the ICR in collaboration with Astex Pharmaceuticals.

A new study sheds light on the genetic messages encoded by genes within ‘triple negative’ breast cancers – and poses important questions on how they could be better treated in future.